Global Breast Cancer Therapeutics Market Outlook, 2031

The global breast cancer therapeutics industry covers medicines used to treat breast cancer, the most commonly diagnosed cancer worldwide, with more than two million new cases a year according to the International Agency for Research on Cancer. Treatment depends on the cancer's subtype, defined by hormone receptor and HER2 status, and includes hormone therapies such as tamoxifen, aromatase inhibitors and fulvestrant; CDK4/6 inhibitors such as Pfizer's Ibrance, Novartis's Kisqali and Lilly's Verzenio; HER2-targeted therapies such as Roche's Herceptin, Perjeta, Phesgo and Kadcyla and AstraZeneca and Daiichi Sankyo's Enhertu; antibody-drug conjugates such as Gilead's Trodelvy and AstraZeneca and Daiichi Sankyo's Datroway; PI3K, AKT and PARP inhibitors such as Novartis's Piqray, AstraZeneca's Truqap and Lynparza, Pfizer's Talzenna and Roche's Itovebi; oral selective oestrogen receptor degraders such as Menarini's Orserdu and Lilly's Inluriyo; immunotherapy with Merck's Keytruda for triple-negative disease; and chemotherapy. Biosimilars of trastuzumab and pertuzumab from Samsung Bioepis, Celltrion, Biocon, Amgen and others have lowered prices of older HER2 drugs. Breast cancer therapeutics is one of the largest oncology markets, and AstraZeneca, Roche, Novartis, Pfizer, Lilly, Gilead, Merck and Daiichi Sankyo are the leading companies. Breast cancer treatment has changed rapidly since 2020, particularly through antibody-drug conjugates and new endocrine-based therapies. Enhertu transformed HER2-positive treatment and then created new categories with approvals for HER2-low disease in 2022 and HER2-ultralow disease in January 2025, and in late 2025 the FDA approved Enhertu with pertuzumab for first-line HER2-positive metastatic breast cancer based on the DESTINY-Breast09 trial. Datroway was approved for HR-positive, HER2-negative breast cancer in January 2025. CDK4/6 inhibitors expanded into early breast cancer, with Verzenio approved for high-risk early disease and Kisqali approved in September 2024 for a broader early breast cancer population based on the NATALEE trial. Targeted drugs for PIK3CA, AKT and ESR1 mutations have made genomic testing routine in advanced HR-positive disease, with Truqap approved in 2023, Itovebi in October 2024 and Inluriyo, an oral selective oestrogen receptor degrader, in September 2025, while AstraZeneca's camizestrant and Pfizer and Arvinas's vepdegestrant have advanced through late-stage trials. Keytruda became a standard for high-risk early triple-negative breast cancer. Loss of exclusivity is approaching for several major brands, including Ibrance and Perjeta, and trastuzumab biosimilars are widely used, while China's domestic companies, such as Hengrui and Kelun-Biotech, have become important developers of breast cancer drugs. Market Dynamics Market Drivers • Rising Incidence and Longer SurvivalBreast cancer incidence is rising globally because of ageing populations, lifestyle changes and wider screening, with particularly fast increases in Asia, Africa and Latin America. At the same time, better treatments mean that many patients with metastatic disease live for years on successive lines of therapy, increasing the duration of treatment. Early detection programmes identify more patients who receive adjuvant therapies to reduce recurrence risk. • Innovation in Targeted Therapies and Antibody-Drug ConjugatesNew drug classes, including antibody-drug conjugates, CDK4/6 inhibitors, oral selective oestrogen receptor degraders and inhibitors of PI3K, AKT and PARP, have improved outcomes for specific subtypes and mutations. Expanded indications, such as HER2-low and HER2-ultralow disease and early breast cancer, have increased the number of eligible patients. Biomarker testing, including circulating tumour DNA testing for ESR1 mutations, supports precision treatment. Market Challenges • High Costs and Unequal AccessNew breast cancer drugs are expensive, with antibody-drug conjugates and CDK4/6 inhibitors costing more than USD 100,000 a year in the United States. Health technology assessment bodies restrict some treatments, and access in low- and middle-income countries is limited, where breast cancer is often diagnosed late and survival rates are much lower. Long treatment durations and combination regimens add to costs for health systems. • Toxicity and ResistanceAntibody-drug conjugates can cause interstitial lung disease, neutropenia and other side effects, and CDK4/6 inhibitors can cause neutropenia and fatigue. Many patients eventually develop resistance to endocrine therapy, CDK4/6 inhibitors and HER2-targeted drugs. Triple-negative breast cancer remains difficult to treat, and managing side effects and sequencing multiple therapies are ongoing challenges for oncologists. Market Trends • Moving Antibody-Drug Conjugates Into Earlier TreatmentAntibody-drug conjugates are moving from later lines of metastatic treatment into first-line and early breast cancer. Enhertu gained first-line HER2-positive approval, trials such as DESTINY-Breast05 and DESTINY-Breast11 have tested it in early disease, and Trodelvy and Datroway are being studied in first-line triple-negative breast cancer. New antibody-drug conjugates targeting TROP2, HER3 and other antigens are in development, many from Chinese companies. • Next-Generation Endocrine TherapiesOral selective oestrogen receptor degraders, including elacestrant, imlunestrant and camizestrant, and other new endocrine agents, such as the PROTAC degrader vepdegestrant and complete oestrogen receptor antagonists, aim to overcome resistance and replace injectable fulvestrant. Trials are testing switching therapy when ESR1 mutations appear in blood tests before progression, and combining new endocrine drugs with CDK4/6, PI3K or AKT inhibitors. New CDK4 and CDK2 inhibitors are also in development. Segment Analysis Targeted therapies, including CDK4/6 inhibitors and HER2-directed drugs, account for the largest share of breast cancer therapeutics value, while antibody-drug conjugates are the fastest-growing drug class. CDK4/6 inhibitors, including palbociclib, ribociclib and abemaciclib, combined with endocrine therapy, are standard first-line treatment for HR-positive, HER2-negative advanced breast cancer and are increasingly used in early disease, making them one of the largest drug classes by value. HER2-targeted monoclonal antibodies, including trastuzumab, pertuzumab and the fixed-dose subcutaneous combination Phesgo, are used in early and metastatic HER2-positive disease, with trastuzumab biosimilars widely adopted. Antibody-drug conjugates, including trastuzumab deruxtecan, trastuzumab emtansine, sacituzumab govitecan and datopotamab deruxtecan, have become the fastest-growing class. Hormone therapies, including tamoxifen, aromatase inhibitors such as letrozole, anastrozole and exemestane, fulvestrant and oral selective oestrogen receptor degraders such as elacestrant and imlunestrant, remain the backbone of HR-positive treatment. PI3K, AKT and mTOR inhibitors, including alpelisib, inavolisib, capivasertib and everolimus, target specific mutations. PARP inhibitors, including olaparib and talazoparib, treat patients with BRCA mutations. Immune checkpoint inhibitors, particularly pembrolizumab, are used in triple-negative breast cancer. Tyrosine kinase inhibitors, including tucatinib and neratinib, treat HER2-positive disease. Chemotherapy, including taxanes, anthracyclines, capecitabine and eribulin, remains widely used, particularly in triple-negative disease and lower-income countries. HR-positive, HER2-negative breast cancer is the largest subtype and treatment segment, while HER2-positive disease generates high value per patient and triple-negative breast cancer has the greatest unmet need. Hormone receptor-positive, HER2-negative breast cancer accounts for about 70% of cases and is treated with endocrine therapy, CDK4/6 inhibitors, PI3K and AKT pathway inhibitors, oral SERDs, antibody-drug conjugates and chemotherapy, making it the largest segment by patients and value. Within this group, HER2-low and HER2-ultralow tumours, which express small amounts of HER2, became eligible for Enhertu, expanding the use of HER2-directed antibody-drug conjugates. HER2-positive breast cancer, about 15% to 20% of cases, is treated with trastuzumab, pertuzumab, trastuzumab deruxtecan, trastuzumab emtansine, tucatinib and neratinib, and outcomes have improved dramatically with these therapies. Triple-negative breast cancer, about 10% to 15% of cases, is more aggressive and more common in younger women and women of African ancestry, and is treated with chemotherapy, pembrolizumab, sacituzumab govitecan and PARP inhibitors for BRCA carriers. By stage, early breast cancer treatment includes neoadjuvant and adjuvant therapy to prevent recurrence, and metastatic breast cancer treatment involves successive lines of therapy over months or years. BRCA-mutated breast cancer and inflammatory breast cancer form distinct subgroups. Male breast cancer is rare and treated similarly to female disease. Intravenous therapies account for a large share of breast cancer drug value, while oral targeted therapies and subcutaneous formulations have grown substantially. Intravenous infusion is used for chemotherapy, antibody-drug conjugates such as trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan, intravenous trastuzumab and pertuzumab, and pembrolizumab, administered in hospitals and cancer centres. Oral therapies have become a large share of the market, including CDK4/6 inhibitors, aromatase inhibitors, tamoxifen, oral SERDs, PI3K and AKT inhibitors, PARP inhibitors, tyrosine kinase inhibitors and capecitabine, allowing patients to take treatment at home for long periods. Subcutaneous formulations, including subcutaneous trastuzumab and Phesgo, reduce administration time from hours to minutes and have been widely adopted in Europe and increasingly in the United States. Intramuscular injection is used for fulvestrant and for goserelin and leuprolide to suppress ovarian function in premenopausal women. Oral SERDs could replace much injectable fulvestrant use. Supportive care drugs, including antiemetics, bone-modifying agents such as denosumab and zoledronic acid, and growth factors, are given by various routes. Subcutaneous formulations of pembrolizumab and other antibodies are being introduced, further reducing time in infusion chairs. Hospital pharmacies and cancer centres account for most breast cancer drug value, while specialty and retail pharmacies distribute a growing share of oral targeted and hormone therapies. Hospital pharmacies and cancer centres supply intravenous chemotherapy, antibody-drug conjugates, HER2 antibodies and immunotherapy, and they are the main channel for high-value breast cancer drugs. Outpatient oncology clinics, including community oncology practices in the United States, administer infusions and prescribe oral therapies. Specialty pharmacies dispense oral CDK4/6 inhibitors, PI3K and AKT inhibitors, PARP inhibitors, oral SERDs and tyrosine kinase inhibitors, managing reimbursement, patient support and monitoring. Retail pharmacies dispense generic hormone therapies such as tamoxifen, letrozole and anastrozole, which patients take for five to ten years. Medically integrated dispensing, where oncology practices dispense oral drugs directly, has grown in the United States. Online and mail-order pharmacies deliver oral drugs to patients' homes. Government tenders and national procurement are important in Europe, China and emerging markets, where trastuzumab biosimilars and generic hormone therapies are bought in large volumes. Patient assistance programmes and access initiatives, including partnerships with the WHO and non-profit organisations, aim to improve access in lower-income countries. Regional Analysis North America leads the breast cancer therapeutics market because of high drug prices, rapid adoption of new targeted therapies and antibody-drug conjugates, and widespread biomarker testing, while Asia-Pacific is the fastest-growing region with rising incidence and a strong domestic drug development industry in China. North America, led by the United States, accounts for the largest share of breast cancer drug revenue. The United States has high screening rates, broad access to genomic testing and rapid uptake of new drugs, and the FDA approved many breast cancer therapies between 2023 and 2025, including Truqap, Itovebi, Datroway, Inluriyo and new indications for Enhertu and Kisqali. Medicare price negotiation has begun to affect oncology, with Ibrance selected for negotiation in the second round, and biosimilars of trastuzumab and pertuzumab are reducing costs. Europe is the second largest market, with strong use of subcutaneous HER2 therapies, trastuzumab biosimilars and CDK4/6 inhibitors, but health technology assessment and budget constraints can delay access to new drugs. Germany, France, the UK, Italy and Spain are the largest markets. Asia-Pacific is the fastest-growing region, with breast cancer incidence rising in China, India, Japan and Southeast Asia. China has become a major market and a centre of drug development, with Hengrui, Kelun-Biotech, RemeGen and others developing antibody-drug conjugates and targeted drugs, and national reimbursement negotiations expanding access. Japan is a large market with high adoption of new therapies, including Enhertu from Daiichi Sankyo. India has a large and growing number of breast cancer cases, often diagnosed late, and relies heavily on biosimilars and generics. Latin America, the Middle East and Africa face rising incidence and limited access to advanced drugs, with survival rates in sub-Saharan Africa much lower than in high-income countries. Key Developments Late 2025: Enhertu plus pertuzumab was approved for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed a 44% reduction in the risk of progression or death versus the standard regimen. September 2025: Eli Lilly's oral selective oestrogen receptor degrader was approved for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after endocrine therapy. January 2025: AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate datopotamab deruxtecan was approved for previously treated HR-positive, HER2-negative metastatic breast cancer. January 2025: The FDA approved trastuzumab deruxtecan for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after one or more endocrine therapies, based on DESTINY-Breast06. October 2024: Roche's PI3K-alpha inhibitor was approved with palbociclib and fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. September 2024: Novartis's ribociclib was approved with an aromatase inhibitor for adjuvant treatment of HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence. Considered in this report • Historic Year: 2020 • Base Year: 2025 • Estimated Year: 2026 • Forecast Year: 2031 Aspects covered in this report • Global Breast Cancer Therapeutics Market with its value and forecast along with its segments • Various drivers and challenges • Ongoing trends and developments • Top profiled companies • Strategic recommendation By Drug Class • CDK4/6 Inhibitors • HER2-Targeted Therapies • Antibody-Drug Conjugates • Hormone Therapies • PI3K, AKT and mTOR Inhibitors • PARP Inhibitors • Immunotherapy • Chemotherapy By Cancer Subtype • HR-Positive, HER2-Negative • HER2-Positive • Triple-Negative • HER2-Low and HER2-Ultralow By Route of Administration • Intravenous • Oral • Subcutaneous • Intramuscular By Distribution Channel • Hospital Pharmacies and Cancer Centres • Specialty Pharmacies • Retail Pharmacies • Online Pharmacies

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Ask an Expert

Sikandar Kesari

Research Analyst

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now